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Abstract
Background: There is common belief among some medical researchers that if a potential
surrogate endpoint is highly correlated with a true endpoint, then a positive (or negative) difference
in potential surrogate endpoints between randomization groups would imply a positive (or
negative) difference in unobserved true endpoints between randomization groups. We investigate
this belief when the potential surrogate and unobserved true endpoints are perfectly correlated
within each randomization group.
Methods: We use a graphical approach. The vertical axis is the unobserved true endpoint and the
horizontal axis is the potential surrogate endpoint. Perfect correlation within each randomization
group implies that, for each randomization group, potential surrogate and true endpoints are
related by a straight line. In this scenario the investigator does not know the slopes or intercepts.
We consider a plausible example where the slope of the line is higher for the experimental group
than for the control group.
Results: In our example with unknown lines, a decrease in mean potential surrogate endpoints
from control to experimental groups corresponds to an increase in mean true endpoint from
control to experimental groups. Thus the potential surrogate endpoints give the wrong inference.
Similar results hold for binary potential surrogate and true outcomes (although the notion of
correlation does not apply). The potential surrogate endpointwould give the correct inference if
either (i) the unknown lines for the two group coincided, which means that the distribution of true
endpoint conditional on potential surrogate endpoint does not depend on treatment group, which
is called the Prentice Criterion or (ii) if one could accurately predict the lines based on data from
prior studies.
Conclusion: Perfect correlation between potential surrogate and unobserved true outcomes
within randomized groups does not guarantee correct inference based on a potential surrogate
endpoint. Even in early phase trials, investigators should not base conclusions on potential
surrogate endpoints in which the only validation is high correlation with the true endpoint within
a group.
Background
A potential surrogate endpoint is an endpoint obtained
sooner, at less cost, or less invasively than the true end-
point of interest. When using a potential surrogate end-
point, one would like to make the same inference as if one
had observed a true endpoint (i.e. a health outcome).
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Working Group [2] gave various examples where prelimi-
nary inference based on a potential surrogate endpoint
was contradicted by later studies using important health
outcomes. As another example, it has long been assumed
that postmenopausal hormone replacement therapy
(HRT) with estrogen and progestin would decrease the
risk of cardiac disease in women-in part due to the facts
that (1) hormonal therapy lowers serum cholesterol, and
(2) people with low cholesterol generally have a lowered
risk of cardiac disease. However direct assessment of this
hypothesis in a randomized placebo controlled trial
showed that HRT actually increased the incidence of car-
diac events [3].
Fleming and DeMets [1] wrote "A correlate does not a sur-
rogate make" and said that "it is a common misconcep-
tion that if an outcome is correlated (that is correlated
with true clinical outcome) it can be used as a valid surro-
gate endpoint..". They added that arequirement for a valid
surrogate is that" the effect of the intervention on the
potential surrogate endpoint predicts the effect on clinical
outcome---a much stronger condition than correlation."
Using schema for causal pathways, Fleming and DeMets
[1] showed why a potential surrogate endpoint can fail to
provide correct inference about the true endpoint. How-
ever Fleming and DeMets [1] did not show why perfect
correlation of potential surrogate and true endpoints is
insufficient for correct prediction of the true endpoint. A
reader of Fleming and DeMets [1] might incorrectly con-
clude that the failure of potential surrogate endpoints
only occurs with small or moderate correlations between
potential surrogate and true endpoints, but not with per-
fect correlation within randomized groups. More specifi-
cally, some investigators believe that that if they have
evidence of a very high correlation between the potential
surrogate and the true outcome in each treatment group in
a previous study, they can make reliable inference about
true outcome in a new study with only a surrogate end-
point. The main purpose of this paper is to show graphi-
cally that even a perfect correlate within a randomized
group does not a valid surrogate make.
Methods
To investigate the validity of a potential surrogate end-
point that is perfectly correlated with true outcomes
within randomized groups, we created the graphic in Fig-
ure 1 for measured outcomes. The graphic applies to a
hypothetical randomized trial, where E stands for experi-
mental group and C stands for control group. The hori-
zontal axis is the potential surrogate endpoint and the
vertical axis is the unobserved true endpoint. Assuming
perfect correlation, the individual data points for poten-
tial surrogate and unobserved true endpoints lie on
straight lines for groups E and C.
In this simple example the unobserved true endpoint is
proportional to the potential surrogate endpoint, so the
intercept for both lines is zero. However qualitatively sim-
ilar results would hold when the two lines have different
intercepts. In our example the onlydifference between the
lines for groups E and C is that the slopes differ. In partic-
ular, the slope of the line relating potential surrogate and
true endpoints for group E is higher than that for group C.
To graphically find the mean value of a true endpoint cor-
responding to the mean value of potential surrogate end-
point, one draws a vertical line from the mean value of the
potential surrogate endpoint to the line relating potential
surrogate and true endpoint, and then a horizontal line
leftward to the axis for the true endpoint.
The graphic also applies when the potential surrogate and
true outcomes are binary. Of course with binary end-
points the notion of perfect correlation does not apply.
However, with binary endpoints, one obtains straight
lines, so the graphic is applicable. For example, suppose
the potential surrogate endpoint is the presence or
absence of adenoma and the true endpoint is the presence
or absence of colorectal cancer. In that case the horizontal
Graphical depiction of incorrect inference based on surro-gage endpoints. The graph shows perf ctly correlated results (nam ly a stra ght line) for t  relationship betweet  a  true outcomes for a ontrol group C and xp ri-menta  gr p EFi ure 1
Graphical depiction of incorrect inference based on surro-
gage endpoints. The graph shows perfectly correlated results 
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gate and true outcomes for a control group C and experi-
mental group E. The mean surrogate outcome in the E group 
 is smaller than the mean surrogate outcome in the C 
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tical axis is the unobserved fraction of subjects who would
get colorectal cancer. For each randomization group there
is a line relating the fraction of subjects with adenoma to
the unobserved fraction with colorectal cancer. (Each line
is constructed by connecting the point representing the
proportion with the true endpoint when the surrogate
endpoint is 0 with the point representing the proportion
with true endpoint when the surrogate endpoint is 1). The
lines in Figure 1 represent one example with a binary sur-
rogate endpoint.
Suppose that an investigator only knows from prior stud-
ies that the potential surrogate and true endpoints are per-
fectly correlated within randomization group (and does
not know the slopes or intercepts). Or suppose the surro-
gate and true endpoints are binary, so there are two
straight lines (but with unknown slopes or intercepts),
one for each randomization group. Will the use of a
potential surrogate endpoint to replace the unobserved
true endpoint give qualitatively the correct results? In
other words, will a decrease (increase) in the mean poten-
tial surrogate endpoint or the fraction with the surrogate
endpoint necessarily imply a decrease (increase) in the
mean true endpoint or the fraction with the true
endpoint?
Results
In the graphic in Figure 1, the mean value for the potential
surrogate endpoint for group E, denoted by , is smaller
than the mean value of the potential surrogate endpoint
for group C, denote by . Because of the perfect correla-
tion between potential surrogate and true endpoints, one
might naively think that the mean for the true endpoint
for group E, denoted by , would be smaller than the
mean value of the true endpoint for group C, denote by
. However if we examine the graphic the opposite is
true. Using the graphic to go from potential surrogate
value to the true value (with a vertical line upwards and a
horizontal line to the left), we see that, in fact, , is larger
than , so the naive conclusion is erroneous.
With binary data,  and  represent the fraction of sub-
jects in the experimental and control groups with the sur-
rogate endpoint, and  and  represent the fraction of
subjects in the experimental and control groups with the
true endpoint. Based on this graphic it is possible that a
decrease in the fraction of subjects with adenoma would
correspond to an increase in the fraction of subjects with
colorectal cancer.
One could create a similar graphic that shows that no
change in the surrogate endpoint corresponds to either a
decrease or increase in the true endpoint, or that an
increase in the surrogate endpoint could lead to a decrease
in the true endpoint.
Discussion
Plausibility of Figure 1
We showed graphically that perfect correlation does not
guarantee correct inference when a potential surrogate
endpoint replaces a true endpoint. The underlying reason
is that the line predicting true endpoint from potential
surrogate endpoint has a sufficiently different slope for
each randomization group to make a substantial differ-
ence in the conclusion. In one possible scenario the inter-
vention reduces the value of the surrogateendpoint that is
observed without affecting the true endpoint, thereby
increasing the slope.
With binary outcomes, different slopes can readily arise
because of unobserved heterogeneity in the potential sur-
rogate endpoint. As an example consider adenoma (yes or
no) as a potential surrogate endpoint for the true outcome
of colorectal cancer (yes or no). Two recent randomized
trials [4,5] showed that aspirin versus placebo lowers the
risk of adenomas. Can one conclude that aspirin lowers
the risk of colorectal cancer? An editorial on these trials
[6] states "given the belief that the development of most
colorectal cancers follows a sequence leading from ade-
noma to carcinoma, a clinical trial in which aspirin
reduced the rate of recurrence of adenomas might make a
compelling case for its effectiveness." However we disa-
gree (and the editorial later comes to a similar conclu-
sion). Under the single pathway hypothesis, if the
probability of adenoma is zero, the probability or colorec-
tal cancer is zero regardless of the intervention (as there is
no other way to get colorectal cancer). Thus, in terms of
our graphic, the single pathway hypothesis implies that
the intercepts of the lines for each group are 0, as in Figure
1. However the slopes can differ substantially due to het-
erogeneity of adenomas, for example in a spectrum of his-
tological types and sizes [7].
To better understand the role of heterogeneity, we follow
Schatzkin and Gail [8], and suppose that there are two
types of adenomas: "bad" adenomas that have the poten-
tial to develop into colorectal cancer and "innocent" ade-
nomas that do not. Let πz denote the probability an
adenoma in randomization group z is "bad." Let φz denote
the probability of colorectal cancer arising from a "bad"
adenoma in randomization group z. Also let ωz denote the
probability of any adenoma in group z. The larger slope in
the experimental than the control group in Figure 1 would
occur if φEπE > φCπC. The leftward shift of the vertical line
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omized trial of finasteride versus placebo [9] where the
potential surrogate endpoint was the probability of pros-
tatecancer. A true definitive endpoint would be the prob-
ability of death from prostate cancer. In this trial,
heterogeneity was observed in the form of high-grade
prostate cancer versus other histological grades of prostate
cancer. Relative to the placebo group, the finasteride
group consisted of a greater fraction of men with high-
grade prostate cancer (πE > πC) but a smaller fraction with
any prostate cancer (ωE < ωC). Because individuals with
high-grade prostate cancer generally have a greater risk of
prostate cancer mortality, we have φE > φC. If the risk of
prostate cancer mortality with other histological grades of
prostate cancer is minimal, the situation is mathemati-
cally similar to the aforementioned hypothetical example
with "bad" and "innocent" adenomas, except that that the
fraction "bad" is observed. There is a greater slope with the
finasteride group (φEπE > φCπC) and a smaller value frac-
tion with the surrogate with the finasteride group (ωE <ωC), which corresponds to Figure 1.
Graphical Representation of the Prentice Criterion
For valid hypothesis testing based on a surrogate endpoint
that replaces a true endpoint, Prentice developed three cri-
teria [10]. The major one, subsequently called the Prentice
Criterion, is that the distribution of true endpoint given
the potential surrogate endpoint does not depend on
treatment group [10]. Our graphic shows that if the poten-
tial surrogate endpoint is a perfect correlate for a true end-
point (even if the slopes and intercepts of the lines were
unknown) and if the Prentice Criterion holds, one would
obtain the correct inference about the true endpoint based
on the potential surrogate endpoint. Graphically, the
Prentice Criterion implies that the lines for groups E and
C coincide, so a decrease in the mean potential surrogate
endpoint would always translate into a decrease in the
mean true endpoint. Wang and Taylor [11] developed a
similar graphic to help explain their proposed statistic, the
proportion of treatment effect summarized by the poten-
tial surrogate, which indicates the appropriateness of the
Prentice Criterion.
Inference Without the Prentice Criterion
Other approaches to inference with surrogate endpoints
involve predicting the true endpoint conditional on the
surrogate endpoint (and using estimates based on data
from previous studies). This use of potential surrogate
endpoints to predict true endpoints differs from the use of
auxiliary variables to predict true endpoint. An auxiliary
variable is a variable that occurs after randomization and
before a true endpoint that is missing in some but not all
subjects. (See [12] and references therein which discuss
the role of auxiliary variables in increasing efficiency or
reducing bias.) In contrast a potential surrogate endpoint
occurs before a true endpoint that is missing in all sub-
jects.
If one could accurately predict the slopes and intercepts of
lines in Figure 1 based on data from previous studies, one
could obtain the correct inference even if the Prentice Cri-
terion did not hold (i.e. even if the lines did not coincide).
For example, in Figure 1, if the slopes and intercepts of the
lines were accurately predicted, one could correctly pre-
dict that the experimental intervention increases the mean
value of the true endpoint despite the decrease in the
mean value of the potential surrogate endpoint (and in
fact obtain estimates and confidence intervals for the pre-
dicted increase in the true endpoint). Unfortunately, this
situation is infrequent. In practice, sufficiently accurate
prediction of the lines based on previous data is difficult
because of sampling variability in the estimates of the
intercepts and slopes of each line and because each previ-
ous study will likely generate a different line, even without
sampling variability, due to differences in interventions.
(Although in practice, the only relevant part of the lines
occurs at the mean values of the surrogate endpoint in the
new study).
Another approach for predicting true endpoint from a
potential surrogate endpoint is the "meta-analytic"
approach [13,14]. The meta-analytic approach is not
reflected in Figure 1 because it does not involve the distri-
bution of the true outcome conditional on the potential
surrogate endpoint (i.e. the slanted lines). Instead each
previous trial generatestwo regressions: one for the effect
of intervention on potential surrogate endpoint and one
for the effect of intervention on the true endpoint. The
coefficients for these two regressions are treated as ran-
dom variables with a joint distribution over all trials. The
estimated parameters from this joint distribution are used
to predict the difference in mean true endpoints in a new
trial given the mean values of the potential surrogate end-
points in the new trial. Unfortunately, there are infre-
quently sufficient data to use this method routinely, and
confidence intervals can be very wide due to between-
study variation [13].
A third approach for predicting true endpoints from a
potential surrogate endpoint in a randomized trial is a
counterfactual approach based on the potential surrogates
that would occur, if contrary to fact, individuals were ran-
domized to a different group [15]. Estimates come from a
previous study but this could be extended to multiple pre-
vious studies. Because counterfactual outcomes are not
observed, additional assumptions are needed for
inference.
In all these approaches there is a fundamental assumption
that the relationship between the potential surrogate andPage 4 of 5
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relationship in the new study under investigation. Besides
accounting for the variability in this relationship (in addi-
tion to sampling variability), one needs to restrict the pre-
vious studies to those involving similar interventions
although, as discussed below, that is not a guarantee of
valid inference.
Additional Caveats with Potential Surrogate Endpoints
The use of surrogate endpoints is particularly attractive for
studies of complex chronic disease since occurrence of the
true endpoint may take years. However, it is precisely
because of the complexity of the diseases that assessment
of potential surrogate endpoints is so difficult. There are
likely to be multiple causal pathways to the true disease
endpoint. Different interventions may exert their biologic
effects on different pathways.
This is why it is particularly hazardous to use even an
"established " surrogate endpoint (or a potential surrogate
endpoint "validated" via multiple previous studies) for
one class of drug to assess another class of drugs. For
example, the statin class of drugs lowers serum cholesterol
and lowers cardiovascular event rates, including mortal-
ity. However HRT with combined estrogen plus progestin
lowers serum cholesterol but increases cardiovascular
event rates. Presumably HRT exerts it harm via another
(dominant) causal pathway, such as the induction of a
hypercoagulable sate in the coronary arteries. New molec-
ular insights into pathogenesis suggest that cancer patho-
genesis is at least as complex as this situation, involving
numerous causal pathways.
Another cautionary note is important. If an intervention
induces harmful side effects, it is risky to draw conclusions
from the potential surrogate endpoint based only infer-
ence regarding the true endpoint. There may be harms
that occur after the time the potential surrogate endpoint
is observed that are not well predicted by the potential
surrogate endpoint. Under these circumstances, even if
the two lines in Figure 1 were superimposed, acceptance
of the potential surrogate endpoint could still lead to
harm.
Conclusion
Sometimes potential surrogate endpoints are justified
because they are highly correlated with the true endpoint
in other studies. As illustrated here, even with known per-
fect correlation within randomized groups, one cannot
rely on the potential surrogate endpoint for valid infer-
ence about the true endpoint, as even the direction of the
effect could be the opposite with true and potential surro-
gate endpoints. Thus, even in preliminary trials, investiga-
tors should not base conclusions on potential surrogate
endpoints in which the only validation is high correlation
with the true endpoint.
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